Integrating novel primary- and secondary-prevention strategies: The next challenge for cervical cancer control

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1725-1733

  Mayrand, Marie Hélène ^a   Franco, Eduardo L ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; Pap test; screening; vaccination

Indexed keywords

ALUMINUM VACCINE; AS04 VACCINE; PLACEBO; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ARTICLE; CANCER SCREENING; CLINICAL TRIAL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 78650225684     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.141     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2002).
2. Action Cancer Ontario (ACO): Le Cancer Chez les Jeunes Adultes au Canada. ACO, Toronto, Canada (2006).
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), S1-S10 (2006).
4. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F: Carcinogenicity of human papillomaviruses. Lancet Oncol. 6(4), 204 (2005).
5. Walboomers JMM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1), 12-19 (1999).
6. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 370 (9590), 890-907 (2007).
7. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV: Epidemiologic classifcation of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (6), 518-527 (2003). (Pubitemid 36159887)
8. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classifcation of papillomaviruses. Virology 324(1), 17-27 (2004).
9. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl. 1), S1-S15 (2006).
10. Bouvard V, Baan R, Straif K et al.: A review of human carcinogens - part B: biological agents. Lancet Oncol. 10(4), 321-322 (2009).
11. Munoz N, Bosch FX, Castellsague X et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111(2), 278-285 (2004).
12. Khan MJ, Castle PE, Lorincz AT et al.: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specifc HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005).
13. Syrjanen K, Hakama M, Saarikoski S et al.: Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex. Transm. Dis. 17(1), 15-19 (1990).
14. Hildesheim A, Schiffman MH, Gravitt PE et al.: Persistence of type-specifc human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169(2), 235-240 (1994).
15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338(7), 423-428 (1998).
16. Moscicki AB, Shiboski S, Broering J et al.: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Pediatr. 132(2), 277-284 (1998).
17. Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl Cancer Inst. Monogr. 203(31), 14-19 (2003).
18. Ho GYF, Burk RD, Klein S et al.: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl Cancer Inst. Monogr. 87(18), 1365-1371 (1995).
19. Kjaer SK, Van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL: Type specifc persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 (7364), 572-579 (2002).
20. Koutsky L, Holmes KK, Critchlow CW: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327 (18), 1272-1278 (1992).
21. Moscicki AB, Shiboski S, Hills NK et al.: Regression of low-grade squamous intraepithelial lesions in young women. Lancet 364(9446), 1678-1683 (2004).
22. Saslow D, Castle PE, Cox JT et al.: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57(1), 7-28 (2007).
23. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol. 197(4), 340-345 (2007). (Pubitemid 47464166)
24. Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12(2), 186-192 (1993).
25. McCredie MR, Sharples KJ, Paul C et al.: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9(5), 425-434 (2008).
26. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G: A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int. J. Cancer 118 (4), 791-796 (2006).
27. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007). (Pubitemid 46740303)
28. Paavonen J, Naud P, Salmeron J et al.: Effcacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): fnal analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009).
29. FUTURE. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
30. Joura EA, Leodolter S, Hernandez-Avila M et al.: Effcacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574), 1693-1702 (2007).
31. Ault KA: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369(9576), 1861-1868 (2007).
32. Harper DM, Franco EL, Wheeler CM et al.: Sustained effcacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
33. GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski B, de Borba PC et al.: Sustained effcacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374(9706), 1975-1985 (2009).
34. Hildesheim A, Herrero R, Wacholder S et al.: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7), 743-753 (2007).
35. Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 33(ACS-2), 1-31 (2007).
36. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER: Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-2), 1-24 (2007).
37. Spence AR, Goggin P, Franco EL: Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev. Med. 45(2-3), 93-106 (2007).
38. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalitites: a systematic review. Ann. Intern. Med. 132 (10), 810-819 (2000).
39. Austin RM, Ramzy I: Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. A review of accumulated data. Acta Cytol. 42(1), 178-184 (1998).
40. Saint M, Gildengorin G, Sawaya GF: Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. Am. J. Obstet. Gynecol. 192(2), 414-421 (2005).
41. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N: Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol. Assess. 8(20), 1-78 (2004).
42. Davey E, Barrat A, Irwig L, Chan SF, Macaskill P, Mannes P: Effect of study design and quality on unsatisfactory rates, cytology classifcations, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367 (9505), 122-132 (2006).
43. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J: Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol. 111(1), 167-177 (2008).
44. Krahn M, McLachlin M, Rosen B et al.: Systematic Review and Cost-Effectiveness Analysis of Screening for Cervical Cancer Using Liquid-Based Technology Canadian Agency for Drugs and Technologies in Health, Technology Overview 40, Ottawa, Canada (2008).
45. Ronco G, Cuzick J, Pierotti P et al.: Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 335(7609), 28 (2007).
46. Bernstein SJ, Sanchez-Ramos L, Ndubisi B: Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am. J. Obstet. Gynecol. 185(2), 308-317 (2001).
47. Abulafa O, Pezzullo JC, Sherer DM: Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol. Oncol. 90(1), 137-144 (2003).
48. Liu S, Semenciw R, Mao Y: Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 164(8), 1151-1152 (2001).
49. Bray F, Loos AH, McCarron P et al.: Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol. Biomarkers Prev. 14(3), 677-686 (2005).
50. Shaw PA: Lessons from the audit of invasive cervical cancer. Cytopathology 13(1), 1-3 (2002).
51. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197(4), 346-355 (2007). (Pubitemid 47464164)
52. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3), S78-S89 (2006).
53. Cuzick J, Arbyn M, Sankaranarayanan R et al.: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10), K29-K41 (2008).
54. Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 59(1), 27-41 (2009).
55. ACOG Committee on Practice Bulletins - Gynecology: ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet. Gynecol. 114(6), 1409-1420 (2009).
56. Naucler P, Ryd W, Tornberg S et al.: Effcacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl Cancer Inst. 101(2), 88-99 (2009).
57. Leinonen M, Nieminen P, Kotaniemi-Talonen L et al.: Age-specifc evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101(23), 1612-1623 (2009).
58. Berkhof J, Coupé VM, Bogaards JA et al.: The health and economic effects of HPV DNA screening in the netherlands. Int. J. Cancer 127(9), 2147-2158 (2010).
59. Dillner J, Rebolj M, Birembaut P et al.: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, A1754 (2008).
60. Gok M, Heideman DAM, van Kemenade FJ et al.: HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340, C1040 (2010).
61. Zhou XH, Obuchowski NA: Statistical Methods in Diagnostic Medicine. John Wiley and Sons Inc., New York, NY, USA (2002).
62. Taube A: Sensitivity, specifcity and predictive values: a graphical approach. Statistics Med. 5(6), 585-591 (1986).
63. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S: Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), S171-177 (2006).
64. Franco EL, Cuzick J: Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26(Suppl.), A16-A23 (2008).
65. Altman DG, Bland JM: Diagnostic tests 2: predictive values. BMJ 309 (6947), 102 (1994).
66. Armitage P, Berry G: Diagnostic tests and screening procedures. In: Statistical Methods in Medical Research. 3rd edition. Blackwell Scientifc Publications, Oxford, UK, 522-529 (1994).
67. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F: The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40(6), 478-485 (2009).